NADIM II: Neo-Adjuvant Immunotherapy
NCT03838159
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
90
Enrollment
OTHER
Sponsor class
Conditions
Non Small Cell Lung Cancer
Interventions
DRUG:
Paclitaxel
DRUG:
Carboplatin
DRUG:
Nivolumab
Sponsor
Fundación GECP